BioCentury
ARTICLE | Clinical News

RAAV2/2_ND4: Phase III amended

September 19, 2016 7:00 AM UTC

GenSight amended the ongoing, double-blind, sham-controlled, international Phase III REVERSE trial evaluating single intravitreal injections of GS010 to include patients ages 15-18. The trial now plan...